Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boehringer Ingelheim

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT01721837

1160.170

Details and patient eligibility

About

Non-interventional, observational study of physicians' use of Dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment

Enrollment: 4,340 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with atrial fibrillation foreseen for Pradaxa anticoagulation according to physician's decision for stroke prevention
• patients with mild or moderate renal impairment
• age >= 18 years at enrollment

Exclusion criteria

• severe renal impairment (Creatinine Clearance < 30 ml/min)

Trial design

4,340 participants in 1 patient group

Atrial fibrillation and mild to moderate renal impairment